Results 151 to 160 of about 265,886 (307)

What's in a Name--Neoadjuvant [PDF]

JNCI Journal of the National Cancer Institute, 1988
openaire   +2 more sources

Impact of Infratemporal Fossa Clearance on Survival in Advanced Buccal Mucosa Cancers

Head &Neck, EarlyView.
ABSTRACT Introduction Buccal mucosa cancers are the most prevalent oral cavity cancers in South Asia, often attributed to widespread tobacco use. The current NCCN guidelines generally advise against primary surgery for locally very advanced (cT4b) buccal cancers involving the masticatory space and infratemporal fossa (ITF).
Sudhir Nair, Rathan Shetty, Amit Bhawalkar, Poonam Joshi, Arjun Singh, Hitesh Singhavi, Jitendra Kumar Sharma, Shwetabh Sinha, Anuj Kumar, Sarbani Ghosh Laskar, Amit Joshi, Pankaj Chaturvedi   +11 more
wiley   +1 more source

Local immunotherapy in the neoadjuvant treatment of cancer: optimizing efficacy while limiting toxicity? [PDF]

J Immunother Cancer
Strikwerda MA, Hoeijmakers LL, Veenstra SPGR, Van Den Eertwegh AJM, Labots M, Blank CU, Mom CH, De Gruijl TD.   +7 more
europepmc   +1 more source

Cigarette Smoke Exposure Attenuates T2R‐Mediated Apoptosis in Head and Neck Squamous Cell Carcinoma

Head &Neck, EarlyView.
ABSTRACT Background Tobacco use is associated with worse outcomes in head and neck squamous cell carcinoma (HNSCC). Bitter taste receptor (T2R) activation induces apoptosis via calcium‐dependent signaling, and higher T2R expression correlates with increased survival in HNSCC.
Kyle Polen, Sarah Sywanycz, Gavin Turner, Brianna L. Hill, Lily Huang, Zoey A. Miller, Casey Hanna, Lovely Raghav, Devraj Basu, Robert J. Lee, Ryan M. Carey   +10 more
wiley   +1 more source

Neoadjuvant Therapy in Locally Advanced Rectal Cancer-What Result Should We Expect? [PDF]

Medicina (Kaunas)
Stefan RE, Constantin A, Dinu D, Achim F, Rotariu A, Grama F, Liscu HD, Iordache L, Scripcariu DV, Rasuceanu A, Constantinoiu S, Predescu D.   +11 more
europepmc   +1 more source

Systemic Treatments for Recurrent or Metastatic Sinonasal Carcinomas: A Retrospective Multicenter Study

Head &Neck, EarlyView.
ABSTRACT Introduction Sinonasal cancers are rare and heterogeneous and pose a therapeutic challenge at an advanced stage due to the lack of data on appropriate systemic management. Methods This retrospective multicenter study analyzed 83 patients with recurrent or metastatic sinonasal carcinomas ineligible for curative treatment, treated in France ...
Marie Degrange, Mathilde Morisseau, Justin Michel, Thibaut Reverdy, Sylvain Morinière, Amaury Daste, Maxime Humbert, Caroline Viala, Pauline Corbaux, Tiffany Darbas, François‐Régis Ferrand, Valentin Favier, Camille Evrard, Diane Evrard, Delphine Farneti, Sarah Betrian‐Lagarde, Victor Sarradin   +16 more
wiley   +1 more source

Neoadjuvant/adjuvant relugolix and enzalutamide for the treatment of high-risk locally advanced prostate cancer: study protocol of the RENAPCA phase Ib trial. [PDF]

BMJ Open
Loper M, Qadar A, Vesely SK, Gunter T, Ayanambakkam A, Wen Y, Cookson M, Stratton K.   +7 more
europepmc   +1 more source

Neoadjuvant Therapy [PDF]

JAMA Oncology, 2015
Howard (Jack) West, Jill Jin
openaire   +1 more source

A multilevel perspective on MSH6‐associated Lynch syndrome: Integrating molecular, biological, and clinical insights

International Journal of Cancer, EarlyView.
Abstract Lynch syndrome (LS) is the most common hereditary colorectal cancer syndrome, caused by a germline pathogenic variant in one of the mismatch repair (MMR) genes. Among these, MSH6‐associated LS represents a distinct subtype with unique molecular and clinical characteristics.
Salwa Ben Yahia, Anne‐Sophie van der Werf‐'t Lam, Madalina Cabuta, Maartje Nielsen, Noah C. Helderman   +4 more
wiley   +1 more source

Coronavirus disease 2019 infection reduces EGFR‐TKI efficacy in non‐small cell lung carcinoma: Real‐world evidence from a multicenter propensity‐matched cohort

International Journal of Cancer, EarlyView.
What's New? Lung cancer patients with COVID‐19 experience significantly increased risk for severe illness and mortality. However, research addressing the effect of COVID‐19 on non‐small cell lung cancer (NSCLC) patients treated with epidermal growth factor receptor (EGFR)‐tyrosine kinase inhibitors (TKIs) remains unknown.
Wenjie Tang, Xiaoxuan Hou, Li Li, Hanxi Zhao, Xiaoyong Tang, Wanqi Zhu, Xiaohui Yan, Jing Liu, Qian Wu, Zhu Qiao, Shanliang Hu, Mingwei Zhang, Xiaolin Li, Peng Xie   +13 more
wiley   +1 more source